To All
Long analysis of bmra by "The Independent Investor".
Found this at aiusa.com
BIOMERICA, Inc.
Ticker: BMRA
Exchange: NASDAQ
Web Site
(Chart Below)
Current Price: 3 1/2 - 3 3/4
52W High: 9.88
52W Low: 1.88
Shares Outstanding: 3.52 Mil
Float: 2.80 Mil
P/E ratio 26.85
Book Value: $0.63
EPS: $0.14
Core Business:
Biomerica develops, manufactures, and markets medical
diagnostic kits and various orthodontic products. Biomerica
also performs specialized diagnostic testing services.
Biomerica, Inc. QUARTERLY SUMMARY
REVENUE 1994 1995 1996 1997
1st Qtr AUG 2,026 2,190 2,329 2,273
2nd Qtr NOV 2,081 2,440 2,273
3rd Qtr FEB 1,944 2,310 2,066
4th Qtr MAY 2,253 2,222 2,813
EPS
1st Qtr AUG -0.025 0.000 0.020 0.040
2nd Qtr NOV -0.010 0.010 0.030
3rd Qtr FEB -0.020 0.010 0.020
4th Qtr MAY 0.030 0.010 0.050
MARKET MAKERS: WDCO SHWD NAWE WEDB HRZG TSCO MASH FAHN SELZ
OFFICERS: Joseph H. Irani, President./ CEO / Treas.
Janet Moore, Secy.
Biomerica, Inc.
1533 Monrovia Avenue
Newport Beach, CA 92663
PHONE: (714) 645-2111
FAX: (714) 722-6674
*************************************************************
Analyst Review
*************************************************************
Biomerica a company which primarily sells diagnostic
testing systems. A majority of their core income is derived
from the sales of these products. And although sales aren't
astronomical to date, the company has still obtained
profitability and EPS of .14. Ironically enough, those numbers
are larger than many other biotech companies in the same sector.
My primary focus is on their release of new products
which, in turn, draws a pathway for a dramatic increase in
revenues and stock price. * On June 12, 1996, the company
reported publicly that they plan to release a tumor diagnostic
testing system on the commercial level. The stock opened that
day at 3 5/8 and closed at 9 3/4! The actual product is slated
for FDA approval within 6 months. When speaking with the company,
they don't plan on having too many hurdles to jump due to the
fact that this product has already been FDA approved for
laboratory use. This product alone should increase revenues
immensely.
Aside from that above, they have several other products
in the pipeline for FDA approval within an estimated 8 months.
The following outlines upcoming FDA approvals:
Ulcer Detection Kit Within 2 months
Yeast Infection Detection Kit Within 5 1/2 months
Tumor Diagnostic Kit Within 6 months
Diabetes Detection Kit Within 8 months
Oral Allergy Therapy Estimated 2 Years
The Diabetes Detection kit is a product which has already
been FDA approved for clinical labs. This detection kit
illustrates symptoms in individuals up to 20 years prior to
obtaining diabetes. The obvious benefit, as explained to me,
is that one has the possibility to prevent it before it actually
happens. Biomerica is looking for FDA approval for commercial
distribution within 8 months. This product has HUGE revenue
potential. The tumor diagnostic kit, which received a phenomenal
response from the market on 6/12/96 speaks for itself.
THE BOTTOM LINE:
Biomerica is a NASDAQ stock with positive earnings and
huge growth potential. Their implementation of new diagnostic
tests kits between now and the next 8 months should get an
extremely positive response from the market. Aside from all
the upcoming publicity, earnings should have a significant
increase over the next year. |
